Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 441000

Next Previous
Search
Drug Profile

SAR 441000

Alternative Names: BNT-131; SAR-441000

Latest Information Update: 05 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; Sanofi
  • Class Antineoplastics; Cytokines; Immunotherapies; RNA
  • Mechanism of Action Cytokine stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants; Interferon alpha expression stimulants; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Solid tumours

Most Recent Events

  • 23 Feb 2024 Discontinued - Phase-I for Malignant melanoma (Combination therapy, Late-stage disease) in Belgium, Germany, USA, France, Netherlands, Spain (Intratumoural) prior to February 2024
  • 23 Feb 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in Spain, Netherlands, France, USA, Germany, Belgium (Intratumoural) prior to February 2024
  • 23 Feb 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in USA, France, Netherlands, Spain, Belgium, Germany (Intratumoural) prior to February 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top